These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

613 related articles for article (PubMed ID: 33946408)

  • 1. Immunotherapy Updates in Advanced Hepatocellular Carcinoma.
    Singh A; Beechinor RJ; Huynh JC; Li D; Dayyani F; Valerin JB; Hendifar A; Gong J; Cho M
    Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments with immunotherapy for hepatocellular carcinoma.
    Waidmann O
    Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.
    Carloni R; Sabbioni S; Rizzo A; Ricci AD; Palloni A; Petrarota C; Cusmai A; Tavolari S; Gadaleta-Caldarola G; Brandi G
    J Hepatocell Carcinoma; 2023; 10():1445-1463. PubMed ID: 37701562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials.
    Ozer M; George A; Goksu SY; George TJ; Sahin I
    Front Oncol; 2021; 11():801379. PubMed ID: 34956912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.
    Kudo M
    Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32349374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma.
    Park R; Eshrat F; Al-Jumayli M; Saeed A; Saeed A
    Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32784389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-PD-1/PD-L1 Blockade Immunotherapy Employed in Treating Hepatitis B Virus Infection-Related Advanced Hepatocellular Carcinoma: A Literature Review.
    Li B; Yan C; Zhu J; Chen X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Jiang W; Fang W
    Front Immunol; 2020; 11():1037. PubMed ID: 32547550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy for hepatocellular carcinoma: Recent advances and future targets.
    Yu SJ
    Pharmacol Ther; 2023 Apr; 244():108387. PubMed ID: 36948423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment.
    Siu EH; Chan AW; Chong CC; Chan SL; Lo KW; Cheung ST
    Transl Gastroenterol Hepatol; 2018; 3():89. PubMed ID: 30603725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies.
    Cheng H; Sun G; Chen H; Li Y; Han Z; Li Y; Zhang P; Yang L; Li Y
    Am J Cancer Res; 2019; 9(8):1536-1545. PubMed ID: 31497341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
    Liu X; Lu Y; Qin S
    Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Dyhl-Polk A; Mikkelsen MK; Ladekarl M; Nielsen DL
    J Clin Med; 2021 Jun; 10(12):. PubMed ID: 34208788
    [No Abstract]   [Full Text] [Related]  

  • 14. Introducing immunotherapy for advanced hepatocellular carcinoma patients: Too early or too fast?
    Lai E; Astara G; Ziranu P; Pretta A; Migliari M; Dubois M; Donisi C; Mariani S; Liscia N; Impera V; Persano M; Tolu S; Balconi F; Pinna G; Spanu D; Pireddu A; Saba G; Camera S; Musio F; Puzzoni M; Pusceddu V; Madeddu C; Casadei Gardini A; Scartozzi M
    Crit Rev Oncol Hematol; 2021 Jan; 157():103167. PubMed ID: 33271389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date.
    Raybould AL; Sanoff H
    J Hepatocell Carcinoma; 2020; 7():133-142. PubMed ID: 32984090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for advanced hepatocellular carcinoma, where are we?
    Zhang L; Ding J; Li HY; Wang ZH; Wu J
    Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188441. PubMed ID: 33007432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives.
    Xu W; Liu K; Chen M; Sun JY; McCaughan GW; Lu XJ; Ji J
    Ther Adv Med Oncol; 2019; 11():1758835919862692. PubMed ID: 31384311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapeutic Approaches for Treating Hepatocellular Carcinoma.
    Shen W; Chen Y; Lei P; Sheldon M; Sun Y; Yao F; Ma L
    Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indoleamine 2,3-dioxygenase provides adaptive resistance to immune checkpoint inhibitors in hepatocellular carcinoma.
    Brown ZJ; Yu SJ; Heinrich B; Ma C; Fu Q; Sandhu M; Agdashian D; Zhang Q; Korangy F; Greten TF
    Cancer Immunol Immunother; 2018 Aug; 67(8):1305-1315. PubMed ID: 29959458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Highlighting novel targets in immunotherapy for liver cancer.
    Ruff SM; Shannon AH; Beane JD; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2022; 16(11-12):1029-1041. PubMed ID: 36404729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.